by Eric Christianson | Jan 21, 2024 | Respiratory Medication and Disease State Clinical Pearls
There are so many inhalers on the market for asthma and COPD. LABA, LAMA, and ICS products are getting so hard to keep track of! Honestly, it gets a little overwhelming at times to remember them all by brand name and what category and classification they fall into. My...
by Eric Christianson | Jan 17, 2024 | Drug Interaction Case Studies and Education For Pharmacists, Uncategorized
In the challenging world of pharmacology, recognizing drug interactions is paramount to ensuring patient safety and optimal treatment outcomes. To make this complex subject more engaging and accessible, we’ve introduced a unique approach – a crossword puzzle...
by Eric Christianson | Jan 14, 2024 | Cardiovascular Medication and Disease State Clinical Pearls
Fenofibrate is a lipid-lowering medication indicated as monotherapy to treat primary hyperlipidemia, mixed dyslipidemia, and hypertriglyceridemia. While this medication has been around for many years, its formulation has continued to evolve. The different fenofibrate...
by Eric Christianson | Jan 10, 2024 | Infectious Disease and Oncology Medication and Disease State Clinical Pearls
To be 100% transparent, I have never personally seen a case of tendon rupture that was likely due to quinolones. I have heard of one from another colleague. It is a very rare adverse effect that has been reported in numerous case studies. What I want you to be aware...
by Eric Christianson | Jan 7, 2024 | Infectious Disease and Oncology Medication and Disease State Clinical Pearls
As much as I would like to say I’ve never seen a patient have a pressure ulcer infection, I have. Pressure ulcer infections can be an issue in my geriatric population. There are numerous clinical pearls to remember in managing these types of infections. First...
